448 related articles for article (PubMed ID: 16249734)
1. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
3. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
Chen KH; Lee CY; Wu FL; Yang CY; Yeh CC; Hu RH; Tsai MK
J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
[TBL] [Abstract][Full Text] [Related]
4. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
5. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
7. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Webster AC; Lee VW; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2006 Apr; (2):CD004290. PubMed ID: 16625599
[TBL] [Abstract][Full Text] [Related]
8. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
9. The role of proliferation signal inhibitors in post-transplant malignancies.
Gutiérrez-Dalmau A; Campistol JM
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i11-6. PubMed ID: 17360768
[TBL] [Abstract][Full Text] [Related]
10. Conversion therapy to everolimus in renal transplant recipients: results after one year.
Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
[TBL] [Abstract][Full Text] [Related]
11. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
[TBL] [Abstract][Full Text] [Related]
12. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
13. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
Bhat M; Watt KD
Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
[TBL] [Abstract][Full Text] [Related]
14. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
Klintmalm GB; Saab S; Hong JC; Nashan B
Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
[TBL] [Abstract][Full Text] [Related]
15. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
Malvezzi P; Jouve T; Rostaing L
Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
[TBL] [Abstract][Full Text] [Related]
16. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
[TBL] [Abstract][Full Text] [Related]
17. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
18. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens.
Mithani Z; Gralla J; Adebiyi O; Klem P; Cooper JE; Wiseman AC
Exp Clin Transplant; 2018 Feb; 16(1):23-30. PubMed ID: 28332959
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant de novo malignancies in renal transplant recipients: the past and present.
Kauffman HM; Cherikh WS; McBride MA; Cheng Y; Hanto DW
Transpl Int; 2006 Aug; 19(8):607-20. PubMed ID: 16827677
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
Bhat M; Mara K; Dierkhising R; Watt KDS
Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
